King of Prussia, PA – According to filings with the U.S. Securities and Exchange Commission, Maxona Pharmaceuticals is raising $10,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Shahin Fatholahi played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Maxona Pharmaceuticals

MAXONA was founded with the goal of addressing the needs of those searching for safe and efficacious remedies as alternatives to NSAIDs and opioid analgesics for the treatment of pain. MAXONA will undertake a staged approach to developing MAX-001 as a platform for treatment of moderate to severe pain: Stage 1 – Acute pain. Stage 2 – Chronic pain & additional other dosage forms and indications some of which are considered as orphan disorders. MAXONA is poised to leverage MAX-001 and build a pipeline of novel therapeutics focused on various pain indications by capitalizing on the existing extensive worldwide safety and efficacy data available as a result of nearly four decades of use. We have adopted a comprehensive patent strategy and built a suite of applied and issued patents covering multiple Compositions of Matter and Methods of Use for MAX-001 targeted at a variety of disorders of pain.

To learn more about Maxona Pharmaceuticals, visit http://maxonapharm.com/

Contact:
Shahin Fatholahi, President and Chief Executive Officer
484-684-7737
https://www.linkedin.com/in/shawnfatholahi/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved